The U.S. Food and Drug Administration has accepted a New Drug Application for BBP-418 and granted it priority review [1, 2].
This decision is significant because BBP-418 is being developed to treat Limb-Girdle Muscular Dystrophy type 2I/R9 (LGMD2I/R9) [1, 3]. There are currently no approved therapies for this specific rare form of muscular dystrophy [3, 4].
BridgeBio Pharma submitted the application to address the unmet medical needs of patients suffering from the condition [3]. The FDA's priority review status is designed to expedite the evaluation of drugs that, if approved, could provide a significant improvement in the safety or effectiveness of the treatment of a serious condition [1, 2].
The agency has set a PDUFA target action date of Nov. 27, 2026 [2]. This date represents the deadline by which the FDA intends to complete its review and issue a decision on whether the drug can be marketed in the U.S. [2].
If the therapy receives regulatory approval, BridgeBio expects a U.S. launch timeframe in late 2026 or early 2027 [3]. The company has previously highlighted data regarding muscle weakness to support the filing [4].
LGMD2I/R9 is a genetic disorder that causes progressive weakness in the muscles of the hips and shoulders. Because the condition is rare, the priority review process helps accelerate the timeline for potential patient access to a first-in-class treatment [3, 4].
“BBP-418 could become the first approved therapy for individuals living with LGMD2I/R9.”
The granting of priority review indicates that the FDA recognizes the critical lack of treatment options for LGMD2I/R9. While acceptance of the application does not guarantee approval, it moves the drug into an accelerated timeline, potentially bringing a first-of-its-kind therapy to market by early 2027.
